Cargando…
Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
Despite the efficacy of decitabine to myelodysplastic syndrome (MDS), there is a wide range of responses, and no definite predictive marker has been identified. This study aimed to describe the efficacy of decitabine and to identify potential predictors of response and survival in patients with MDS....
Autores principales: | Jung, Hyun Ae, Maeng, Chi Hoon, Kim, Moonjin, Kim, Sungmin, Jung, Chul Won, Jang, Jun Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599296/ https://www.ncbi.nlm.nih.gov/pubmed/25938546 |
Ejemplares similares
-
Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome
por: Jung, Hyun Ae, et al.
Publicado: (2021) -
Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007) -
A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome
por: Jeong, Seong Hyun, et al.
Publicado: (2015) -
Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011) -
Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)